Background Hyaluronic acid (HA) fillers are quite commonly used since several years for soft tissue augmentation. Aim The purpose of this study was to evaluate primarily the safety and secondarily the clinical effectiveness of Cross‐Linked Sodium Hyaluronate 24 mg with Lidocaine 3 mg (Jeunesso 24L) injection, in subjects undergoing treatment for facial wrinkles and lip augmentation. Method Patients between the age groups of 18 and 75 years, who were seeking soft tissue augmentation treatment on the face and with wrinkle severity score (WSS) ≥2 for bilateral Nasolabial Folds (NLF), were included in the study. The appropriate quantity of the filler was injected at the treatment site. Clinical efficacy assessments were conducted independently at 3 and 6 months after baseline. Clinical efficacy was assessed using Wrinkle Severity Rating Scale (WSRS) and a Global Aesthetic Improvement Scale (GAIS). Results The mean pain score was found to be 2.57 ± 2.06 immediately after injection which was reduced to 0.1 ± 0.675 at 15 min and this further subsided to “No Pain” in any of the participants at 60 min post the injection. WSRS mean score before treatment was 2.76, which were significantly reduced to 2.14, at 3 months. Majority of participants found an improvement in the marionette line severity. Also, significant improvements were seen in the perioral and lip areas. The Study filler was well‐tolerated and no side effects were reported. Conclusion The study indicates that this particular filler, HA+L, is useful for cosmetic improvements in the nasolabial folds and for enhancement of the lips.
Breast cancer (BC) exhibit a high level of mortality rate and incidence but a comprehensive treatment is unavailable, which can successfully eradicate this fatal disease. Novel therapeutic strategies have been intensively studied to eradicate BC, including the use of traditional medicines and phytochemical (herbal compounds). These compounds have been studied in many aspects, such as targeting cell cycle and key tumor-associated metabolic pathways. In this study, we reviewed the literature for the potential therapeutic application of herbal compounds against breast cancer. Several terms, including "Herbal compounds", "Breast Cancer" and "Traditional medicines", were searched in PubMed and Web of Science databases. The search results were narrowed down using many filters and the resultant literature was critically analyzed. The enormous number of articles showed the promising potential of herbal compounds as anticancer therapy. The comprehensive evaluation of the literature suggested the anti-angiogenic, anti-proliferative, anticancer stem cells, anti-inflammatory/antioxidant, anti-metastatic, and epigenetic effects of herbal compounds as anticancer effects against BC. Despite this enormous data, there is lack of sufficient demonstration of the consumption of herbal compounds in a regular as anticancer strategy in clinical trials. Therefore, given its promising anticancer potential, focus should be shifted towards the regular use of herbal compounds in anticancer strategies.
Therapeutics against breast cancer is a major research field, due to inefficiency or partial efficiency of existing therapeutics. An urge to discover better therapeutics always persists. Our objective is to study salicin against breast cancer cells, in order to find its therapeutic properties. To study the effect of salicin on breast cancer cells, we performed MTT assay on MCF-7 (hormone positive) and MDA-MB-231 (triple negative) breast cancer cell lines, we did brine shrimp lethality test (BSLT) assay to see the lethal effects of salicin. By the help of bioinformatics we tried to locate the targets that delineate salicin activity. Salicin was docked with estrogen receptor (ER), progesterone receptor (PR) and Human epidermal growth factor receptor 2 (HER2) to study its binding efficiency and possible targets of salicin. Salicin remarkably reduces cell viability both in MCF-7 and MDA-MB-231, along with being lethal to brine shrimps. These results together opine that salicin can be an effective therapeutics against breast cancer cells. The mechanism of action of salicin is probably through ER, PR and HER2 receptors because it can efficiently bind these receptors with minimum energy required for binding. This explains that salicin can easily bind to these receptors. These results together opine that salicin can be an effective therapeutics against breast cancer cells. The mechanism of action of salicin is probably through ER, PR and HER2 receptors because it can efficiently bind these receptors with minimum binding energy. ER, PR and HER2 are major reasons behind the disease pathogenicity depending on the type of breast cancer. According to our results salicin may either induce apoptosis or reduce cellular mitosis both via P53 dependent and independent pathway, which makes salicin a good choice of both hormone positive and negative breast cancer cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.